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Introduction
The term thrombosis refers to the formation of a clot
[thrombus] inside a blood vessel and an embolus is a frag-
ment of the thrombus that breaks off and travels in the blood
until it settles at a sight of vascular narrowing. Deep vein
thrombosis (DVT), usually involving a leg vein, and pul-
monary embolism (PE) are the manifestations of the same
disease entity and can be collectively referred to as venous
thromboembolism (VTE).1 VTE is an important cause of
perioperative morbidity and mortality.1-3 Atleast 30 cases of
DVT identifiable by phlebography can be expected among
100 patients who have undergone general surgical opera-
tions of moderate severity if they are not given perioperative
antithrombotic prophylaxis.2
As there is a scarcity of reliable autopsy data, it is not
clear how often fatal PE occurs after surgery. The risk varies
with the surgical procedure and PE may account for 10% of
all postoperative deaths following hip arthroplasty and fatal
PE accounts for 3-4% of all symptomatic VTE events.1 A
thorough preoperative assessment and preparation before
major surgery must include the issue of the prevention of
DVT and PE in the perioperative period in an attempt to
decrease the incidence of this potentially fatal perioperative
complication. Correct choice of the thromboprophylactic
regime for each patient and initiating it at the right time is
important to decrease the incidence of perioperative VTE. 
Selection of the appropriate prophylactic regime and
providing it for the appropriate duration in the perioperative
period depends not only upon the knowledge of the various
modalities available for the prevention of VTE but also
upon the awareness of the gravity of this complication,
among both the surgeons and the anaesthesiologists. This
article will review the etiology and risk factors of perioper-
ative DVT and PE and the various pharmacological and
non-pharmacological modalities available for its preven-
tion. The term VTE will be used when referring to DVT and
PE together.
Etiology and risk factors
The etiological factors for DVT include venous sta-
sis (reduced blood flow), a hypercoagulable state (potential
for abnormal clot formation) and the presence of vessel
injury (loss of vascular integrity).3 These three factors are
called the Virchow's triad and are common findings in the
postoperative period especially after major surgery. The risk
of symptomatic thromboembolism depends to a large extent
upon the type and duration of surgery, presence of other risk
factors (Table 1), duration and extent of postoperative
immobilization and use or not of thromboprophylactic
measures.4
Age, co-morbids and type of anaesthesia (general or
regional) also contribute to the incidence rate and should be
considered when assessing a patient's risk for postoperative
DVT.3 The incidence of asymptomatic VTE, which is con-
siderably higher than that of symptomatic VTE, has been
reported to be 20-25% after general surgery and 45-60%
after orthopaedic surgery involving the hip or knee. Results
of one study5 showed that neurosurgery involving entry into
brain or meninges and orthopaedic surgery involving the hip
was associated with the highest incidence of symptomatic
thromboembolism. Other procedures found to be associated
with a higher risk in that study included major vascular sur-
gery, small or large bowel resection, radical cystectomy,
gastric bypass for obesity and renal transplantation.
Operations associated with a low risk include laparoscopic
cholecystectomy, appendectomy, inguinal hernia repair,
transurethral resection of prostate, and radical neck dissec-
tion.4 
The incidence of postoperative VTE is low in
patients younger than 40 years and increases with age.6
Prolonged immobilization due to any reason including
stroke, surgery, trauma, and obesity leads to an increased
risk of developing postoperative DVT mainly due to
venous stasis.7 Medical conditions like congestive heart
failure (CHF) and chronic obstructive pulmonary disease
(COPD) are associated with a higher incidence of VTE.8
Cancer is an important risk factor for postoperative VTE.
The reason for this could be that neoplastic cells generate
thrombin and synthesize various procoagulants.9 Oral con-
traceptives containing estrogen and hormone-replacement
therapy increase the risk of VTE especially at the start of
therapy.10
Patients who receive epidural or spinal anaesthesia
have a more than 50% decreased incidence of postoperative
VTE after total hip or knee replacement compared to those
having these surgeries under general anaesthesia.1,11
However, the long-term outcome is not affected by the
anaesthetic technique.12
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Prevention of Venous Thromboembolism 
A variety of non-pharmacological and pharmacolog-
ical agents are available for the prophylaxis of VTE (Table
2). 
The selection of the prophylactic regimen should be
individualized for each patient depending upon the surgical
procedure, individual patient risk factors and safety and effi-
cacy of the thromboprophylactic agent. In this context the
patients at low risk for VTE are those under 40 years of age
having general surgical, urologic and gynaecological non-
cancer surgeries of short duration (< 60 min).2 Moderate risk
includes patients less than 40 years with no added risk fac-
tors having major surgery or those between 40 and 60 years
having no added risk factors for VTE undergoing minor sur-
gery or patients less than 40 years but having risk factors for
VTE, undergoing minor procedures (Table 3). High-risk
patients are those over 60 years of age, having additional risk
factors for VTE and undergoing minor surgical procedures
or those over 40 years with no additional risk factors having
major surgery. Patients at very high risk for VTE are those
above 40 years with multiple VTE risk factors having major
surgery (Table 3).2,4
Table 3. Postoperative Venous Thromboembolism: Risk stratification.
The risk of thrombosis and bleeding should be
weighed for each patient and the timing and dosage of the
prophylactic agent adjusted accordingly. A description of
the various non-pharmacological and pharmacological
agents available for the prophylaxis of VTE follows.
Non Pharmacologic Modalities 
Elastic Compression Stockings
Graduated-compression stockings can provide ade-
quate prophylaxis in patients at low risk for DVT.13 The
stockings should be applied prior to surgery and continued
until full ambulation.3 They improve venous flow from the
foot to the knee, but improperly fitting stockings will cause
a reversed effect leading to more harm than benefit.13 The
main advantages of elastic compression stockings are that
they are cheap, convenient, easy to use and properly fitting
stockings, when applied correctly, have proven efficacy for
patients at low risk for DVT.2-4,13 Although they do not pro-
vide adequate prophylaxis when used alone in patients at
moderate to high risk for perioperative VTE, they enhance
the effect of other thromboprophylactic modalities4, and
should be used in all surgical patients at risk unless there is
Table 1. Risk factors for postoperative thromboembolism.
Venous stasis
Bed rest
Trauma
Recent surgery
Stroke
Venous insufficiency
Congestive heart failure
Pregnancy
Morbid obesity
History of venous stasis
Hypercoagulability
Estrogen oral contraceptives
Postoperative state
Deficiency of protein C or protein S
Antithrombin III resistance
Inflammatory bowel disease
Malignancy
Post trauma
Abnormality of the vessel wall
Trauma
Surgery
Varicose veins
Vasculitis
Drug induced irritation
Table 2. Modalities for VTE Prophylaxis.
Non-Pharmacological Modalities
Elastic compression stockings
Intermittent pneumatic compression devices
Early ambulation
Inferior vena cava filters
Pharmacological Agents
Low dose unfractionated heparin
Low molecular weight heparin
Warfarin (low dose / intermediate dose: INR 2.0-3.0)
Aspirin (usually as an adjunct)
Dextran (not popular currently)
VTE: Venous thromboembolism.
Age Presence of Extent of Surgery Degree of Risk
(Years) Risk Factors
< 40 No Minor Low
< 40 No Major Moderate
40-60 No Minor Moderate
Any age Yes Minor Moderate
> 60 Yes Minor High
> 40 ± Major High
< 40 Yes Major High
> 40 Multiple Major Very high
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Thus, properly fitting elastic stockings should be
used as an adjunct to other thromboprophylactic modalities
for moderate to high risk patients and may be used as a sole
agent in patients at low risk.  
Intermittent Pneumatic Compression Devices
These devices cause intermittent external compres-
sion of the legs and thighs with inflatable cuffs thereby pump-
ing venous blood and reducing stasis. Intermittent pneumatic
compression (IPC) devices are also said to aid the clearance
of prothrombotic clotting factors and increase endogenous
fibrinolysis by stimulating the vascular endothelial wall14
although, more recently, another study has not found this
increase in fibrinolysis with IPC devices.15 Improper applica-
tion of these devices could be a frequent reason for the fail-
ure of this form of prophylaxis against DVT16, and probably
for this reason this form of prophylaxis has not been found to
be effective in obese patients. 
In addition to the calf and thigh IPC devices, foot
pumps are also available which compress the planter venous
plexus, but they have not been studied extensively.17 IPC
devices are safe and are especially useful in patients who are
at an increased risk of bleeding with anticoagulant therapy.
For the same reason these devices are attractive for prophy-
laxis in patients who have undergone neurosurgical proce-
dures.18 These devices should be used in conjunction with
pharmacological methods of VTE prevention in patients
who are at a high risk of perioperative VTE but can be used
as sole agents for those who are at a moderate risk, while in
case of gynaecological surgery they can be used as sole
agents even in high risk cancer patients.19
Early Ambulation
Early ambulation should be strongly encouraged in
all post surgical patients. It has proved to be associated with
a lower incidence of both symptomatic and ultrasonically
diagnosed thromboembolism after hip surgery.20 Early
ambulation, in older persons is associated with fewer com-
plications and shorter hospital stay and in low risk general,
urologic and gynaecologic surgeries, early ambulation
alongwith elastic stockings can be used for prophylaxis of
VTE without the addition of pharmacologic prophylactic
agents.1
Inferior Vena Cava Filters
Inferior vena cava (IVC) filters are meant to inter-
rupt blood flow to prevent pulmonary embolization.21 Their
use is recommended when there is a failure of or contraindi-
cation to anticoagulation and when anticoagulation leads to
serious hemorrhage and has to be discontinued. In the last
situation an IVC filter should especially be considered for
patients with recent VTE.21 These filters are also appropri-
ate for patients with VTE who have recurrent pulmonary
embolism despite adequate anticoagulant therapy.1 The
complications of IVC filters include IVC thrombosis, filter
migration, recurrent DVT and postphlebitic syndrome21
which is a chronic complication of venous thrombosis that
consists of pain, swelling and occasionally ulceration of the
skin of legs. Thus, IVC filters should be used only when
strongly indicated and temporary filters should be preferred. 
Pharmacological Thromboprophylaxis
The most widely used agents for the prevention of
perioperative VTE include unfractionated heparin (UH),
low molecular weight heparin (LMWH), warfarin and anti-
platelet agents. This article will briefly review these agents.
These agents differ in their efficacy and in the seriousness
of their main side effect, that is, bleeding. The choice of the
antithrombotic agent should be individualized depending
upon the presence of risk factors, the type of surgery and the
risk of hemorrhagic complications. 
Unfractionated Heparin
Small subcutaneous  doses of heparin given in a dose
of 5000 IU two or three times daily have shown to be effec-
tive in decreasing the incidence of fatal postoperative PE in
patients at a moderate risk of VTE.22 The first dose can be
given two hours preoperatively but should be started earlier
in admitted patients who are confined to bed. Postoperative
initiation of UH has also been shown to be effective.23
Low dose UH (5000 IU 8-12 hourly subcutaneous-
ly) is a useful prophylactic agent for most general surgical,
gynaecologic and urologic surgical patients and non-phar-
macological modalities like elastic stockings and IPC
devices may be added in higher-risk patients.3,22 Low dose
UH is less effective compared with LMWH in very high
risk neurosurgeries and orthopaedic surgeries.24 It is there-
fore not the prophylactic agent of choice for very high risk
procedures. Its main side effects include bleeding and
heparin induced thrombocytopenia [HIT]. Haemorrhagic
complication and serious bleeding is rare as long as there is
no other haemorrhagic diathesis.22 HIT associated with UH
has been shown to have a strong association with postoper-
ative VTE.25
Low Molecular Weight Heparin
The common LMWH preparations include enoxa-
parin, dalteparin, rogiparin and tinzaparin. Enoxaparin
(claxane) and dalteparin (fragmin) are currently available in
Pakistan. LMWH exerts its effect by the inhibition of factor
Xa mediated by antithrombin. There is evidence that the
incidence of bleeding with LMWH is lower compared with
low dose UH and the efficacy has been found to be equiva-
lent.24 This makes LMWH more attractive in many surgical
patients. A longer biological half life and predictable plas-
ma concentration of LMWH allow 
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it to be administered once or twice daily in a fixed
dose without the need for laboratory tests.26 This enables
outpatient management when extended DVT prophylaxis is
required, thus reducing inpatient costs. The usual dosage is
enoxaparin 30mg subcutaneously (s/c) 12 hourly or 40mg
s/c once daily or dalteparin 2500-5000 IU daily s/c. 
There have been some unfavorable reports of the use
of LMWH for thromboprophylaxis. In one report an unex-
pectedly high rate of DVT followed abdominal surgery
despite daily doses of LMWH at recommended levels.27 No
clear reasons for the increased rate of DVT encountered in
this study came forth and other workers did not obtain a
similar result.24,26 In elective surgery of hip and knee, a once
daily dose of LMWH [Logiparin] was associated with a
higher incidence of serious bleeding complications when
compared to warfarin prophylaxis with an INR of 2.0 to 3.0,
although LMWH was found to be more effective.28
However, the overall review of LMWH2-4,24,26 suggests that
it is an effective and safe agent that can be used on an out-
patient basis. 
Warfarin
Warfarin, a vitamin K antagonist, is a useful agent for
VTE prophylaxis, especially in high risk patients.29 It exerts
its action by interfering with the carboxylation of coagula-
tion factors II, VII, IX, X and proteins C and S.3 The half life
of these coagulation factors varies widely, from approxi-
mately 6 hours for factor VII to 50 hours for factor II. This
is the reason for the long time required for return of normal
coagulation following discontinuation of warfarin. Increased
warfarin effect occurs in severe hepatic or renal insufficien-
cy as well as with acute alcohol use, decreased dietary intake
of vitamin K and decreased protein binding of warfarin.3 The
dose recommended for DVT prophylaxis is usually adequate
to treat an established but undetected thrombosis.2,4
The prothrombin time and the International
Normalized Ratio (INR) are used to monitor therapy with
warfarin. The target range of INR for an individual patient
is guided by the risk of thromboembolism and the nature of
surgery. The target INR of 2.0 to 3.0 has been found to be
effective.29 The potential for bleeding complications is a
concern and adequate monitoring is essential, but the inci-
dence has not been found to be troublesome if the INR is
kept between 2.0 to 3.0.29 For the purpose of VTE prophy-
laxis warfarin use is indicated primarily for very high risk
patients with lower limb orthopaedic surgery, neurosurgery
or those with malignant lesions.3 It is useful for patients
who require extended thromboprophylaxis especially those
undergoing total hip arthroplasty. It can be started either the
night before surgery or immediately after surgery. It can
also be started 10-14 days preoperatively to maintain an
INR of about 1.5 and then increasing the dose postopera-
tively to achieve an INR of 2.5.4,29 Elderly patients or those
with low serum albumin levels require lower doses of war-
farin.
Antiplatelet Agents
Aspirin has been studied as a prophylactic agent
against DVT but its use for this purpose is controversial.30
It is not recommended as a sole prophylactic agent for peri-
operative VTE prevention, but research has shown a role of
aspirin for VTE prevention after hip fracture surgeries when
used in combination with other thromboprophylactic
agents.31 It may also provide additional benefit to patients
with cardiovascular disease. Patient's and physician's famil-
iarity with aspirin makes it a useful agent to be prescribed at
discharge for additional long term protection when indicat-
ed. 
Other Agents
The dextrans are branched chain polysaccharides,
which increase flow in the microcirculation32 and have
shown to prevent VTE. They have to be administered intra-
venously and can lead to allergic reactions including ana-
phylaxis. For this reasons they are not currently being used
for VTE prophylaxis.
Hirudin is a constituent of leech saliva and has anti-
coagulant properties. Recombinant DNA techniques are
being used to produce biologically active compounds relat-
ed to hirudin. One of these agents, disirudin, has been com-
pared with enoxaparin for VTE prophylaxis and has been
found to be more effective with a similar safety profile.33
These agents are potent inhibitors of thrombin and their
action is independent of antithrombin III. Other agents are
in different stages of development and require trials to prove
their efficacy and safety. 
Timing and Duration Of Prophylaxis
Optimal timing and duration of prophylaxis is
important, especially in high risk patients. For total hip and
knee replacements LMWH can be started the night before
surgery followed by once daily injections.34 In the United
States the usual practice is to start LMWH postoperatively.
Extending the prophylaxis for 4-6 weeks is recommended
for total hip replacement35 although this is associated with a
modest increase in the risk of minor bleeding.
For patients having other elective surgical proce-
dures, prophylaxis should be started preoperatively, that is,
as soon as the risk of developing DVT begins, with an
appropriate combination of non-pharmacological and phar-
macological modalities, and continued during hospitaliza-
tion.2-4 Extended prophylaxis should be provided to patients
at a higher risk of VTE. These include patients with active
cancer, with history of VTE, patients who are obese or can-
not ambulate for any reason. Either LMWH
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(enoxaparin 40mg or dalteparin 5000 IU once daily
s/c) or warfarin (to keep INR around 2.5) can be used for
extended prophylaxis. Warfarin is cheaper as compared to
LMWH but it requires laboratory monitoring for adequate
anticoagulation and prevention of bleeding complications.
Conclusion
Venous thromboembolism is a major preventable cause
of postoperative morbidity and mortality. When prescribing
thromboprophylaxis for any patient, proper risk stratification
should be implemented so that the risk of bleeding and throm-
boembolism could be balanced. Local practice guidelines
should be developed with a combined effort of the surgeons,
the anaesthesiologists and the physicians, keeping in mind the
availability and cost effectiveness of the various modalities
described for thromboprophylaxis. Pharmacological and non-
pharmacological modalities should be used in appropriate
combinations to achieve effective thromboprophylaxis for each
patient.
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